Wall Street brokerages expect Histogenics Corp (NASDAQ:HSGX) to post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Histogenics’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.11). Histogenics posted earnings per share of ($0.26) during the same quarter last year, which would indicate a positive year-over-year growth rate of 42.3%. The company is expected to announce its next earnings report on Thursday, March 21st.
According to Zacks, analysts expect that Histogenics will report full year earnings of ($0.46) per share for the current fiscal year, with EPS estimates ranging from ($0.54) to ($0.41). For the next financial year, analysts expect that the business will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.78) to ($0.21). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Histogenics.
Histogenics (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05).
HSGX opened at $0.44 on Tuesday. Histogenics has a 1-year low of $0.37 and a 1-year high of $3.35. The firm has a market cap of $12.86 million, a price-to-earnings ratio of -0.45 and a beta of 1.02.
A number of large investors have recently modified their holdings of the business. Renaissance Technologies LLC boosted its position in Histogenics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares during the period. BlackRock Inc. boosted its position in Histogenics by 72.0% during the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 22,927 shares during the period. DRW Securities LLC bought a new position in Histogenics during the second quarter worth about $242,000. JPMorgan Chase & Co. bought a new position in Histogenics during the first quarter worth about $320,000. Finally, Virtu Financial LLC bought a new position in Histogenics during the third quarter worth about $117,000. Hedge funds and other institutional investors own 45.68% of the company’s stock.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Recommended Story: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.